Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
about
Statins for acute coronary syndromeStatins for acute coronary syndromeStatins for acute coronary syndromeDiverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cellsRising statin use and effect on ischemic stroke outcomeDebate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotectionStatin non-adherence: clinical consequences and proposed solutionsStatins in heart failure: do we need another trial?Primary prevention of coronary heart disease in the elderlyEmerging drugs in peripheral arterial diseaseSex difference in the antiplatelet effect of aspirin in patients with strokeStatins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control studyOptimal lipid modification: the rationale for combination therapyHMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statinsNK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cellsStatin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-IModulation of the mevalonate pathway by akt regulates macrophage survival and development of pulmonary fibrosisStatins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophagesLDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?Biodegradable Cable-Tie Rapamycin-eluting Stents.Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data.The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.American Diabetes Association indications for statins in diabetes: is there evidence?Cerebral blood flow velocity and vasomotor reactivity during autonomic challenges in heart failure.Effects of fluvastatin on plasma levels of low-density lipoprotein subfractions, oxidized low-density lipoprotein, and soluble adhesion molecules: a twenty-four-week, open-label, dose-increasing studyEfficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience.Statins induce hypothrombotic states?Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus.Non-lipid-related effects of statins.Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation.Synergistic effect of simvastatin and ezetimibe on lipid and pro-inflammatory profiles in pre-diabetic subjectsStroke: epidemiology, clinical picture, and risk factors--Part I of III.Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol.Renal failure in atherosclerotic renovascular disease: pathogenesis, diagnosis, and intervention.Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injuryPromoting endothelial recovery and reducing neointimal hyperplasia using sequential-like release of acetylsalicylic acid and paclitaxel-loaded biodegradable stentsDiabetes and vascular disease.
P2860
Q24193862-006E7004-8CB0-42FF-8CA2-067978E81053Q24236697-BD6D4CA2-B68B-4EE1-9FA7-85F5D092F58AQ24243557-2637EA59-C007-4E68-80CD-CC6293E8BC0DQ24533532-4754A5AC-6A58-4AA5-9CEF-9C5A89E780D8Q24792305-99546198-37F7-4FED-A8AC-E32FCE912994Q24793416-33EAD1CA-298C-4575-A3CD-5B1569780685Q24793685-0DAF424E-92F8-440A-96FA-E7CFF676C86CQ26748560-C3ED4AA3-A365-483E-8BAC-4E6EF5D00D21Q26998966-8BF88C55-6731-4060-96C7-7CDB3A7263BEQ28165739-62BCA4E4-02E0-45B3-83FE-A38A7D93384FQ28195408-AF4B7113-CA0C-45C9-837E-30B0D37325CDQ28196479-1E67FA40-F6CD-45E5-8B78-BAB86F74C303Q28211027-C6CB48D6-EE50-4931-BA65-68CAE247C976Q28219266-E8439AFD-E04A-48FD-B9B2-0E6B72F236FBQ28344912-F0CC349A-179B-4C43-83A1-6951A87E40D1Q28363802-ED5D0FBE-0406-467A-B64C-C11A309B2C81Q28366335-62B23ECB-0386-4603-84F6-9FFC140A0784Q28385018-ACCBB135-2F59-4DE5-9682-465750D307D3Q28741815-3A8A1CFC-256E-475B-856F-B7D88DE6C8C4Q30422549-8CB0A227-09F9-4FF2-BC72-22F4ED2D63D3Q30849379-56D98547-8DAB-4051-8F3A-6B9B1A6CDFBBQ31005025-B097934D-FFF7-4991-9276-AEC48455F591Q33208345-58BE9928-0001-466D-95D4-D03B9AA6ACBDQ33585657-A8A0DFBE-54B3-4B5B-B471-06D53C95B71DQ33610712-24EE23AC-1DE3-4991-8BCB-E016A1592564Q33623951-ACC86FB0-B623-4DC9-8A97-A6DD0A00A0D8Q33738872-1A908273-F2A1-4F82-8F3F-95891FAAF616Q33815841-BDCC2936-4478-4242-A12A-C3C34B6DF37EQ33826469-768B760C-1AEC-4547-8DBA-D4583EB82EBCQ33868357-9FF3D711-03C4-4ECA-8A57-D80E061C9AC7Q33915449-E1DF7977-CF40-4589-81A9-75C7B937F45DQ33924588-8ABBF1A4-DDED-49F2-9CAB-B574194BE997Q33951689-5936581A-5387-475D-93B2-70C81115F7EEQ33986458-8B501C27-9C89-45D7-8949-F606321188DCQ34099742-69D09D02-2A58-46A9-AFDA-64A66C112BFFQ34122524-B0B86629-488B-49A2-A810-9D39F6DC370AQ34132047-1FA82A20-6040-4370-8F8B-D85C7C7B52F2Q34146989-6FBB3195-7CDA-4EF6-88CA-F69C3F8CA2EAQ34148996-16E43721-3B8B-450B-8451-D944FDA1A340Q34157753-6263E81E-98CB-4642-A4F4-E1BC90E725E3
P2860
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Antiatherothrombotic propertie ...... ardiovascular event reduction.
@en
Antiatherothrombotic propertie ...... ardiovascular event reduction.
@nl
type
label
Antiatherothrombotic propertie ...... ardiovascular event reduction.
@en
Antiatherothrombotic propertie ...... ardiovascular event reduction.
@nl
prefLabel
Antiatherothrombotic propertie ...... ardiovascular event reduction.
@en
Antiatherothrombotic propertie ...... ardiovascular event reduction.
@nl
P356
P1476
Antiatherothrombotic propertie ...... ardiovascular event reduction.
@en
P2093
C C Tangney
R S Rosenson
P304
P356
10.1001/JAMA.279.20.1643
P407
P577
1998-05-01T00:00:00Z